Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Lymphoma 1Graft vs Host Disease 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Maraviroc × Clear all
NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡